Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics (EWTX) filed its Q3 2025 10-Q, reporting a net loss of $40.7 million on operating expenses of $46.9 million. Research and development was $37.5 million and general and administrative was $9.4 million. Interest income contributed $6.2 million.
Liquidity remained strong with cash, cash equivalents and marketable securities of $563.3 million as of September 30, 2025, supported by an April 2025 underwritten registered direct offering of 9,935,419 shares at $20.13 per share for $200.0 million gross ($187.1 million net). For the first nine months, net cash used in operations was $105.2 million, reflecting continued investment in pipeline programs.
The company advanced multiple clinical assets: sevasemten in Phase 2 trials for Becker and Duchenne muscular dystrophy (including a pivotal cohort in Becker), EDG‑7500 in a multipart Phase 2 for hypertrophic cardiomyopathy, and EDG‑15400 in a Phase 1 study. Shares outstanding were 105,761,949 as of September 30, 2025, and 105,868,434 as of October 31, 2025. Management believes current liquidity will fund operations for at least the next 12 months.
Edgewise Therapeutics (EWTX) filed an 8-K stating it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company notes that the information provided under Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and not deemed filed under the Exchange Act.
Edgewise Therapeutics insider transactions by Russell Alan J: The reporting person executed transactions on 08/26/2025. The Form 4 shows an acquisition of 100,000 shares of common stock at a reported price of $0.18 and a sale of 100,000 shares at an average price of $14.5976 (range $14.40 to $14.825). After the non-derivative transactions, the reported beneficial ownership in common stock is 123,400 shares following the acquisition line and 23,400 shares following the sale line. The filing also reports ownership of derivative securities: a stock option (strike $0.18) for 100,000 shares exercisable from 06/27/2021 and expiring 06/27/2032, and a reported number of derivative-linked common shares beneficially owned of 1,247,365. The signature block shows the Form was signed by an attorney-in-fact on 08/28/2025.
Edgewise Therapeutics (EWTX) filed a Form 144 reporting a proposed sale of 100,000 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 08/26/2025 with an aggregate market value of $1,459,760.00. The filing shows 105,345,708 shares outstanding, indicating the proposed sale represents roughly 0.095% of outstanding shares. The shares were acquired on 08/26/2025 by exercise of options under a registered plan and paid in cash the same day. The filing also discloses a prior sale in the past three months: 1,907 shares sold on 08/12/2025 by Alan J Russell for $25,534.73. The filer certifies no undisclosed material adverse information.
Edgewise Therapeutics insider grant: The company reported that Robert Blaustein, Chief Development Officer and director, was granted 17,500 restricted stock units (RSUs) and options to purchase 105,000 shares on 08/12/2025. The RSUs are payable one-for-one upon vesting in four equal annual installments beginning 08/12/2026. The options have an exercise price of $13.39, vest at 1/48th monthly beginning 09/12/2025, and expire 08/12/2035. Following these grants Blaustein beneficially owns 17,500 RSUs and 105,000 option shares directly. The filing was signed by John R. Moore under power of attorney on 08/14/2025.
Insider transactions by John R. Moore at Edgewise Therapeutics (EWTX): The reporting person, General Counsel John R. Moore, recorded transactions on 08/12/2025 showing both equity compensation vesting and a small sale to cover taxes. He had 5,781 RSUs vest (treated as acquired) and sold 2,098 shares in a sell-to-cover at an average price of $13.3924 (trade prices ranged $13.36–$13.49). Following these transactions, Mr. Moore directly beneficially owned 17,344 shares plus outstanding awards and options.
Compensation grants: New awards include 26,875 RSUs (vesting from 08/12/2026) and a 161,250-share stock option with a $13.39 exercise price vesting monthly from 09/12/2025 through 08/12/2035.
Edgewise Therapeutics insider activity: Behrad Derakhshan, Chief Business Officer, had RSUs vest and executed related transactions on 08/12/2025. 5,781 restricted stock units vested and were treated as acquired at $0.00. To satisfy tax withholding on those vested RSUs, 2,491 shares were sold in multiple transactions at an average price of $13.3924 (range $13.36–$13.49). Following the transactions the reporting person beneficially owned 23,645 shares of common stock directly. The filing also reports 30,000 newly granted RSUs (vesting beginning 08/12/2026) and a stock option to purchase 180,000 shares at an exercise price of $13.39 (vesting 1/48th monthly beginning 09/12/2025). The newly vested and granted awards are subject to standard service-based vesting schedules.
Edgewise Therapeutics insider transactions: R. Michael Carruthers, identified as Chief Financial Officer and reporting person, reported multiple equity transactions dated 08/12/2025. He acquired 5,781 shares of common stock and simultaneously sold 1,428 shares at an average price of $13.3924 to satisfy tax withholding from vesting restricted stock units. Following these transactions, he beneficially owned 86,162 shares of common stock. The filing also reports derivative awards: 5,781 vested restricted stock units exercisable into common shares, 26,875 newly granted restricted stock units, and a stock option to purchase 161,250 shares at an exercise price of $13.39, with vesting schedules extending through 2035. The transactions were signed by an attorney-in-fact on 08/14/2025.
Edgewise Therapeutics insider Russell Alan J reported multiple equity transactions on 08/12/2025. He acquired 5,781 shares via vesting of RSUs and sold 1,907 shares in a sell-to-cover to satisfy tax withholding at an average sale price of $13.3924 per share (individual sale prices ranged $13.36–$13.49). After these transactions he beneficially owns 23,400 shares.
The filing also shows newly granted compensation awards: 5,781 RSUs vesting in four equal annual installments beginning 08/12/2025, 28,125 RSUs vesting in four equal annual installments beginning 08/12/2026, and a stock option to purchase 168,750 shares at an exercise price of $13.39 per share exercisable beginning 09/12/2025 with a 08/12/2035 expiration. The report identifies Russell as Chief Scientific Officer and a director.
Edgewise Therapeutics insider transactions: Kevin Koch, President and CEO and director, reported multiple equity awards and a sell-to-cover on 08/12/2025. He received 17,968 RSUs that vested (or were deemed acquired) and an additional 87,500 RSUs granted with staggered vesting beginning 08/12/2026. He was also granted a 525,000-share stock option exercisable at $13.39 per share with monthly vesting starting 09/12/2025. To satisfy tax withholding, 7,972 shares were sold at an average price of $13.3924. Following these transactions, he beneficially owned 30,615 shares directly and 259,554 shares indirectly through family entities.